Dock Line
The eastern part of the UT MD Anderson Cancer Center campus in Houston, with downtown Houston visible in the background, photographed Feb. 29, 2012
The eastern part of the UT MD Anderson campus in Houston, with downtown in the background, photographed Feb. 29, 2012. This is not a picture of the sarcoma study or its patients. A Nov. 19 MD Anderson release describes a new study of ATRX loss in sarcomas. (Nightryder84)

Jane Long

November 20, 2026 · 3 min read

MD Anderson Study Finds ATRX Loss May Mark More Aggressive Sarcomas

A Nov. 19 MD Anderson release describes a Journal of Clinical Investigation study finding that loss of the ATRX gene is linked to poorer sarcoma outcomes and to greater sensitivity, in lab models, to investigational TEAD inhibitors.

Researchers at The University of Texas MD Anderson Cancer Center reported Nov. 19 that sarcomas lacking the ATRX gene tend to be more aggressive and may be more vulnerable to a class of experimental drugs known as TEAD inhibitors.

The MD Anderson release describes the work as identifying ATRX loss as both a marker of poorer outcomes and a potential therapeutic target. The study, published as an in-press preview dated Nov. 10 in The Journal of Clinical Investigation, was led by Kunal Rai, Ph.D., professor of genomic medicine. The findings have not been tested in a completed clinical trial of patients, and the university said additional clinical studies are needed to determine whether TEAD inhibitors will help people with these tumors.

"For many patients with sarcoma, treatment decisions still are not guided by the biology of their tumors," Rai said in the release. "We found that ATRX loss may identify patients who are more likely to benefit from TEAD inhibitors, creating a potential path toward precision medicine for these difficult-to-treat cancers."

Sarcomas are rare cancers with limited treatment options, particularly when the disease spreads, the release said. ATRX is one of the most frequently altered genes in several sarcoma subtypes. The ATRX protein normally helps organize chromatin, the packed complex of DNA and proteins that forms chromosomes. The paper's authors, including first author Ryan A. Denu, M.D., Ph.D., of MD Anderson's Department of Sarcoma Medical Oncology, evaluated tumor samples from patients with soft-tissue and uterine leiomyosarcoma, undifferentiated pleomorphic sarcoma, and dedifferentiated liposarcoma.

According to the paper's abstract, the researchers observed loss of ATRX protein in 14% of soft-tissue leiomyosarcomas (n = 127), 53% of uterine leiomyosarcomas (n = 95), 37% of undifferentiated pleomorphic sarcomas (n = 82), and 8% of dedifferentiated liposarcomas (n = 84). ATRX loss was associated with significantly worse outcomes in uterine leiomyosarcoma, undifferentiated pleomorphic sarcoma, and dedifferentiated liposarcoma. The MD Anderson release summarizes the uterine-leiomyosarcoma figure as "more than half," which matches the 53% reported in the abstract.

In laboratory models, the authors reported that knocking out ATRX in sarcoma cells increased proliferation in cooperation with TP53 deletion and remodeled chromatin. The work points to a signaling path involving PRDM4, YAP1, and TEAD proteins. The abstract says ATRX-deficient cells and sarcoma xenografts were more sensitive to the investigational TEAD inhibitors VT103 and IAG933. The university release likewise said ATRX-deficient models responded better to those two drugs than tumors with intact ATRX, with treatment reducing tumor growth and decreasing activation of TEAD-controlled genes in those models.

Those results are from cells and animal tumor models, not from a randomized trial in people. The inhibitors named in the paper are investigational. The university said that if the findings are validated in future clinical trials, ATRX could become a biomarker to help guide treatment selection, and that the results could also help shape trial design. It did not report that TEAD inhibitors have been approved for sarcoma or that ATRX testing is now a standard part of care.

The research was supported in part by the National Institutes of Health, the QuadW Foundation, the National Leiomyosarcoma Foundation, Conquer Cancer, the ASCO Foundation, the Jay Vernon Jackson Liposarcoma Fund Foundation, and UT MD Anderson institutional funding, the release said. A full list of authors, disclosures, and funding appears with the journal article. The JCI listing identifies the paper as open access, with the digital object identifier 10.1172/JCI201343, and lists coauthors from multiple MD Anderson departments as well as the University of Texas Health Sciences Center at Houston and Rice University, as listed on the paper.

The university presented the work as a step toward matching some sarcoma patients with future targeted therapies, not as a change in standard treatment. Until clinical trials test the idea in people, ATRX loss remains a laboratory and pathology finding with a possible use as a biomarker, and the TEAD inhibitors remain experimental drugs studied in cells and xenografts.